Xinsheng Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xinsheng Zhu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Peng Zhang
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
34 shared publications - Huansha Yu
Experimental Animal Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai China
33 shared publications - Jie Dai
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai China
33 shared publications - Jing Zhang
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
33 shared publications - Lele Zhang
Central Laboratory, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
33 shared publications - Qiangsheng Hu
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
33 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary Metabolomics raw data
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary Metabolomics raw data
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
FigureS1-S11 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary Figures and Figure Legends
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS1-S11 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary Figures and Figure Legends
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary RNA sequencing raw data
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary RNA sequencing raw data
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary Table 1 Primer sequences
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Supplementary Table 1 Primer sequences
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Induction of ferroptosis, a recently defined form of nonapoptotic cell death caused by iron-dependent lipid peroxidation, has emerged as an anticancer strategy. Erastin is a ferroptosis activator that promotes cell death that not only depends on the depletion of cellular cysteine but also relies on mitochondrial oxidative metabolism of glutamine. Here, we demonstrate that ASS1, a key enzyme involved in the urea cycle, plays a crucial role in ferroptosis resistance. Loss of ASS1 increased the sensitivity of non–small cell lung cancer (NSCLC) cells to erastin in vitro and decreased tumor growth in vivo. Metabolomics analysis with stable isotope-labeled glutamine showed that ASS1 promotes reductive carboxylation of cytosolic glutamine and compromises the oxidative tricarboxylic acid cycle from glutamine anaplerosis, reducing mitochondrial-derived lipid reactive oxygen species. Moreover, transcriptome sequencing showed that ASS1 activates the mTORC1–SREBP1–SCD5 axis to promote de novo monounsaturated fatty acid synthesis by using acetyl-CoA derived from the glutamine reductive pathway. Treating ASS1-deficient NSCLC cells with erastin combined with arginine deprivation significantly enhanced cell death compared with either treatment alone. Collectively, these results reveal a previously unknown regulatory role of ASS1 in ferroptosis resistance and provide a potential therapeutic target for ASS1-deficient NSCLC.Significance:ASS1 promotes reductive carboxylation of glutamine and confers ferroptosis resistance, providing multiple treatment options for ASS1-deficient non–small cell lung cancer.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells
Induction of ferroptosis, a recently defined form of nonapoptotic cell death caused by iron-dependent lipid peroxidation, has emerged as an anticancer strategy. Erastin is a ferroptosis activator that promotes cell death that not only depends on the depletion of cellular cysteine but also relies on mitochondrial oxidative metabolism of glutamine. Here, we demonstrate that ASS1, a key enzyme involved in the urea cycle, plays a crucial role in ferroptosis resistance. Loss of ASS1 increased the sensitivity of non–small cell lung cancer (NSCLC) cells to erastin in vitro and decreased tumor growth in vivo. Metabolomics analysis with stable isotope-labeled glutamine showed that ASS1 promotes reductive carboxylation of cytosolic glutamine and compromises the oxidative tricarboxylic acid cycle from glutamine anaplerosis, reducing mitochondrial-derived lipid reactive oxygen species. Moreover, transcriptome sequencing showed that ASS1 activates the mTORC1–SREBP1–SCD5 axis to promote de novo monounsaturated fatty acid synthesis by using acetyl-CoA derived from the glutamine reductive pathway. Treating ASS1-deficient NSCLC cells with erastin combined with arginine deprivation significantly enhanced cell death compared with either treatment alone. Collectively, these results reveal a previously unknown regulatory role of ASS1 in ferroptosis resistance and provide a potential therapeutic target for ASS1-deficient NSCLC.Significance:ASS1 promotes reductive carboxylation of glutamine and confers ferroptosis resistance, providing multiple treatment options for ASS1-deficient non–small cell lung cancer.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
FigureS1-S11 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary Figures and Figure Legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS1-S11 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary Figures and Figure Legends
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary RNA sequencing raw data
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary RNA sequencing raw data
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary Metabolomics raw data
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary Metabolomics raw data
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary Metabolomics raw data
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary Metabolomics raw data
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary RNA sequencing raw data
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells
Supplementary RNA sequencing raw data